NEW YORK MEDICAL COLLEGE
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1860-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.nymc.edu
Clinical Trials
68
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
- Conditions
- CMVAdV InfectionAdV ReactivationAdenovirusCytomegalovirus Infections
- Interventions
- Drug: Standard of Care Antiviral medicationsBiological: Viral CTLs
- First Posted Date
- 2025-11-10
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 69
- Registration Number
- NCT07225972
Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- New York Medical College
- Registration Number
- NCT07077187
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 20
- Registration Number
- NCT07013565
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors
- Conditions
- StrokeAphasia Following Cerebral InfarctionHemiparesis After Stroke
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 28
- Registration Number
- NCT07000019
- Locations
- 🇺🇸
Westchester Medical Center / New York Medical College, Valhalla, New York, United States
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Biological: CD30 CAR T-cell
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 21
- Registration Number
- NCT06617286
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
Aflibercept 8 mg Shows Extended Dosing Intervals in Real-World nAMD Treatment
Real-world data from nearly 40,000 patients reveals aflibercept 8 mg allows for extended dosing intervals of 2+ weeks in neovascular AMD patients compared to previous anti-VEGF treatments.
Study Reveals Significant Sleep Disruption Among Parents of Children with Atopic Dermatitis
National Health Interview Survey analysis shows 45.2% of parents with children having atopic dermatitis fail to get recommended 7 hours of sleep, compared to 37.1% of other parents.